KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Payables (2019 - 2025)

Royalty Pharma's Payables history spans 7 years, with the latest figure at $19.4 million for Q4 2025.

  • For Q4 2025, Payables rose 45.13% year-over-year to $19.4 million; the TTM value through Dec 2025 reached $19.4 million, up 45.13%, while the annual FY2025 figure was $19.4 million, 45.13% up from the prior year.
  • Payables for Q4 2025 was $19.4 million at Royalty Pharma, down from $41.4 million in the prior quarter.
  • Across five years, Payables topped out at $41.4 million in Q3 2025 and bottomed at $5.6 million in Q4 2021.
  • The 5-year median for Payables is $12.8 million (2022), against an average of $15.3 million.
  • The largest annual shift saw Payables tumbled 72.67% in 2021 before it skyrocketed 303.1% in 2024.
  • A 5-year view of Payables shows it stood at $5.6 million in 2021, then soared by 40.68% to $7.9 million in 2022, then surged by 91.82% to $15.2 million in 2023, then dropped by 11.84% to $13.4 million in 2024, then skyrocketed by 45.13% to $19.4 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Payables are $19.4 million (Q4 2025), $41.4 million (Q3 2025), and $20.2 million (Q2 2025).